Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N07XX13
|
| gptkbp:blackBoxWarning |
thrombocytopenia
nephrotic syndrome |
| gptkbp:CASNumber |
1255984-36-9
|
| gptkbp:chemicalFormula |
C230H309N67O127P19S19
|
| gptkbp:developer |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:genericName |
gptkb:inotersen
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tegsedi
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
antisense oligonucleotide inhibitor of transthyretin (TTR) protein production
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
thrombocytopenia
injection site reactions nephrotic syndrome |
| gptkbp:usedFor |
hereditary transthyretin-mediated amyloidosis
|
| gptkbp:yearOfEMAApproval |
2018
|
| gptkbp:bfsParent |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|